[New assessment method in rheumatoid arthritis].

Area of Science:

• Rheumatology
• Biomarker Discovery
• Clinical Assessment

Context:

• Conventional rheumatoid arthritis (RA) disease activity indices often involve subjective components.
• There is a need for more objective measures to accurately assess RA disease activity.
• The Multi-Biomarker Disease Activity (MBDA) score has emerged as a novel, objective tool.

Purpose:

• To review the utility and application of the MBDA score in managing rheumatoid arthritis.
• To highlight the MBDA score's ability to provide objective disease activity assessment.
• To discuss the predictive value of the MBDA score for RA outcomes.

Summary:

• The MBDA score is a novel, serum-based disease activity assessment tool for RA, ranging from 1-100.
• It is derived from a pre-specified algorithm combining 12 distinct biomarkers.
• The MBDA score reflects current RA disease activity and predicts future radiographic progression and flare risk.

Impact:

• The MBDA score provides a more objective assessment of RA disease activity compared to conventional methods.
• Its predictive capabilities can inform treatment decisions and patient monitoring strategies.
• Utilizing the MBDA score may lead to improved management and outcomes for patients with RA.